New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
List view / Grid view
Filter the results
Researchers found increasing levels of Dnmt3a2 in neurons activated at the time of making a memory, improved its recall in mice.
A new microfluidic technology has been developed which can profile histone modifications with as few as 100 cells per assay.
A new paper describes the first full study of the epigenetics of human tumour organoids, suggesting this could be used to develop novel oncology treatments.
Scientists have showed that a three inhibitors (3i) cocktail could reprogramme fibroblasts to a naïve embryonic stem cell-like state and remove disease-associated epigenetic changes.
Researchers have shown that two epigenetic regulators could be targeted to improve cognitive and behavioural decline in age-related diseases like Alzheimer’s.
A murine study found histone deacetylase 3 (HDAC3) inhibitors reverse epigenetic changes caused by CREBBP mutations found in lymphomas and could be developed into a novel therapy.
A study has demonstrated the success of changing the genome of mice, regulating the production of the C11orf46 gene.
A new discovery that leukaemia type B cells can transform into different cells through epigenetic changes could lead to more effective therapies.
A machine-learning algorithm has been created that automates high-throughput screens of epigenetic medicines.
The basic premise of drug discovery screening necessitates that the biological assays upon which it depends can be performed in a reproducible manner. In addition, the techniques employed must generate results that are biologically relevant and actionable.
Researchers have reported finding on an epigenetic signature in patient cells that appears to predict inflammation risk in Crohn's disease...
Researchers in the U.S. have identified a new link between epigenetic changes in the brains of rats and resulting translational control during fear memory reconsolidation.
Congestive heart failure is a terminal disease that affects nearly 6 million people in the U.S.; yet its management is limited to symptomatic treatments as its causal mechanisms – including its most common form, ischemic cardiomyopathy – are unknown.